Ziqiang Tian

Ziqiang Tian


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
QGQiang Guo
Qiang Guo
HWHaijun Wang
Haijun Wang
YXYanzhao Xu
Yanzhao Xu
MWMingbo Wang
Mingbo Wang
ZTZiqiang Tian
Ziqiang Tian
Emerging studies have indicated that microRNAs (miRNAs/miRs) are involved in regulating non‑small cell lung cancer (NSCLC)‑associated processes. The present study aimed to evaluate the biological roles of miR‑374a‑5p in NSCLC. Using reverse transcription‑quantitative PCR, the expression levels of miR‑374a‑5p were determined in NSCLC cells and a normal cell line. Functional experiments were performed to investigate the functions of miR‑374a‑5p in NSCLC. A luciferase activity reporter assay and rescue experiments were performed to validate NCK adaptor protein 1 (NCK1) as a functional target of miR‑374a‑5p. It was demonstrated that miR‑374a‑5p levels were decreased in NSCLC cell lines compared with those in a normal cell line. Furthermore, overexpression of miR‑374a‑5p inhibited NSCLC cell proliferation and migration in vitro. Of note, NCK1 overexpression reversed the effects of miR‑375a‑5p on NSCLC cell proliferation and migration. The present results confirmed the tumor suppressor role of miR‑374a‑5p via targeting NCK1 in NSCLC, indicating the importance of the miR‑374a‑5p/NCK1 axis in NSCLC.

26 March 2010 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
LLLihua Liu
Lihua Liu
BSBao-En Shan
Bao-En Shan
ZTZiqiang Tian
Ziqiang Tian
MSMeixiang Sang
Meixiang Sang
JAJun Ai
Jun Ai
SWShi-Jie Wang
Shi-Jie Wang
Currently, no satisfactory biomarkers are available to screen for esophageal squamous cell carcinoma (ESCC). The goal of this study was to find biomarkers and establish a serum protein fingerprint model for early diagnosis of ESCC using the ClinProt protocol of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Serum samples were collected from 62 patients with ESCC, nine patients with esophageal adenocarcinoma (EA) and 38 healthy individuals. Proteomic spectra of mass to charge ratio (m/z) were generated following the application of plasma to weak cationic-exchanger magnetic beads (WCX-MB). The spectral data were analyzed using a support vector machine, and potential biomarkers were chosen for system training and used to construct diagnostic models. Three differential patterns were established using MALDI-TOF MS. Pattern 1, consisting of 11 protein peaks, separated ESCC patients from the healthy individuals with a sensitivity of 90.0% and a specificity of 88.4%. Pattern 2, consisting of eight protein peaks, separated ESCC in stage I and stage II from stage III and stage IV with a sensitivity of 92.9% and a specificity of 82.3%. Pattern 3, consisting of seven protein peaks, separated ESCC from EA with a sensitivity of 91.3% and a specificity of 80.0%. These results suggested that MALDI-TOF MS combined with MB separation yields significantly higher sensitivity and specificity for the detection of serum protein in patients with ESCC.

22 February 2024 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
PWPengzeng Wang
Pengzeng Wang
LYLinan Yang
Linan Yang
YGYin Guo
Yin Guo
SQShuliang Qi
Shuliang Qi
JLJia Liang
Jia Liang
ZTZiqiang Tian
Ziqiang Tian

1 July 2024 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Open access
PDF file
GYGuang Yang
Guang Yang
HLHuining Liu
Huining Liu
SXSiwei Xu
Siwei Xu
ZTZiqiang Tian
Ziqiang Tian
Background: Lung cancer is a life-threatening disease that is still prevalent worldwide. This study aims to evaluate the effects of matricin, a sesquiterpene, on the carcinogenic agent benzo(a)pyrene [B(a)P]-induced lung cancer in Swiss albino mice. Methods: Lung cancer was induced by oral administration of B(a)P at 50 mg/kg b. wt. in model Swiss-albino mice (group II) as well in experimental group III, and treated with matricin (100 mg/kg b. wt.) in group III. Upon completion of treatment for 18 weeks, the changes in body weight, tumor formation, enzymatic and non-enzymatic antioxidant levels (GSH, SOD, GPx, GR, QR, CAT), lipid peroxidation (LPO) level, pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), immunoglobulin levels (IgG, IgM), apoptosis markers (Bax, Bcl-xL), tumor markers (carcinoembryogenic antigen (CEA), neuron-specific enolase (NSE)), and histopathological (H&E) alterations were determined. Results: The results indicate that B(a)P caused a significant increase of tumor formation in the lungs, increased tumor markers and inflammatory cytokines in serum, and depletion of enzymatic/ non-enzymatic antioxidants and immunoglobulins, compared to the untreated control group. Matricin treatment significantly reversed the changes caused by B(a)P as evidenced by the biochemical and histopathological assays. Conclusion: The changes caused by matricin clearly indicate the cancer-preventive effects of matricin against B(a)P-induced lung cancer in animal models, which can be attributed to the antioxidant activity, immunomodulation, and mitigation of the NF-kβ pathway.

1 October 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZFZaiwen Fan
Zaiwen Fan
XGXiaonan Gao
Xiaonan Gao
MWMingxia Wang
Mingxia Wang
ZTZiqiang Tian
Ziqiang Tian
Aim: The goal of our study was to investigate the effects of single-dose simvastatin and itraconazole application on the pharmacokinetics of erlotinib in rats. Methods: Twenty-one male Sprague-Dawley rats were randomly divided into 3 groups, including erlotinib combined with simvastatin, erlotinib combined with itraconazole and erlotinib alone groups. The rats were given a single dose of 2 mg/kg simvastatin, 15 mg/kg itraconazole or 0.5% sodium carboxymethyl cellulose followed by 12 mg/kg erlotinib. The concentration of erlotinib in rat plasma was determined by UPLC-MS/MS. As internal standard, tinidazole was used for chromatographic analysis on the Kinetex C18 column (100× 2.1 mm, 2.6 μm). Results: Erlotinib was validated in the calibration range of 5– 1000 ng/mL. The lower limit of quantification (LLOQ) was 5 ng/mL. The inter- and intra-day precisions for erlotinib were less than 10.56%, and the accuracies were in the range of 98.61– 104.99%. The validated UPLC-MS/MS method was successfully applied to this study. Compared with the erlotinib alone group, the values of AUC0-t, AUC0-∞, Cmax, Vz/F and t1/2 in the simvastatin group showed no statistical differences among pharmacokinetic parameters (P> 0.05). However, the values of AUC0-t, AUC0-∞ and Cmax, in the itraconazole group were approximately 1.32-fold, 1.32-fold and 1.34-fold higher, and the CL/F was lower than those in the erlotinib alone group; the difference was statistically significant (P< 0.05). Conclusion: Simvastatin had no significant effect on the pharmacokinetics of erlotinib, whereas co-administration of itraconazole considerably increased the exposure of erlotinib. Therefore, we should pay more attention to the potential drug-drug interaction to ensure safety in cancer patient treatment.